» Articles » PMID: 16369747

Non-small Cell Lung Cancer: Radiation Therapy for Locoregional Recurrence After Complete Resection

Overview
Specialty Oncology
Date 2005 Dec 22
PMID 16369747
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: We investigated patterns of failure after radical radiation therapy in relation to the radiation field in patients with postsurgical locoregional recurrence of non-small cell lung cancer.

Methods: Between 1992 and 2002, 31 patients with locoregional recurrence were treated with radiation therapy. At the time of radiation therapy, the sites of recurrence were the bronchial stump, the regional lymph nodes, the chest wall, and both the regional lymph nodes and the chest wall in 7, 20, 3, and 1 patient, respectively. The prescribed dose was 60 Gy in 30 fractions over 6 weeks in all patients.

Results: The response rate was 87%. The overall 1-year, 2-year, and 4-year Kaplan-Meier survival rates were 61%, 30%, and 15%, respectively, and the median survival time was 14 months. Locoregional relapse with or without distant metastasis occurred in 15 patients (in-field, 7; marginal, 7; out-field, 1), and distant metastasis alone occurred in 7 patients. The sites of marginal relapse were the upper margin in two patients, the ipsilateral margin in one patient, the contralateral margin in one patient, and the lower margin in three patients, respectively (in one patient, the data for marginal relapse overlapped). In all patients with relapse on the lower margin, the mediastinal lymph nodes were dissected at the initial surgery.

Conclusion: Postoperative recurrent non-small cell lung cancer showed distinctive features: the response rate was high, and the incidence of marginal relapse was also high, as in small cell lung cancer. The incidence of lower marginal relapse was high, in contrast to that in surgery-naive patients.

Citing Articles

Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).

Furuta M, Horinouchi H, Yokota I, Yamaguchi T, Itoh S, Fukui T Cancer Sci. 2024; 115(11):3705-3717.

PMID: 39278260 PMC: 11531949. DOI: 10.1111/cas.16340.


Chemo-radiotherapy plus durvalumab for loco-regional relapse of resected NSCLC.

Borghetti P, Imbrescia J, Volpi G, Scotti V, Aquilano M, Bruni A Radiat Oncol. 2022; 17(1):124.

PMID: 35842660 PMC: 9288672. DOI: 10.1186/s13014-022-02084-5.


Salvage radiation therapy for postoperative locoregionally recurrent non-small cell lung cancer: a single-center experience.

Jo Y, Kim S, Song S, Choi E Radiat Oncol J. 2021; 39(3):210-218.

PMID: 34610660 PMC: 8497866. DOI: 10.3857/roj.2021.00696.


Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer.

Lee K, Ahn Y, Pyo H, Noh J, Park S, Kim T Cancer Res Treat. 2018; 51(2):769-776.

PMID: 30205417 PMC: 6473287. DOI: 10.4143/crt.2018.366.


Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer.

Hisakane K, Yoh K, Nakamura N, Udagawa H, Kirita K, Umemura S Medicine (Baltimore). 2018; 96(47):e8635.

PMID: 29381935 PMC: 5708934. DOI: 10.1097/MD.0000000000008635.


References
1.
Onishi H, Araki T, Shirato H, Nagata Y, Hiraoka M, Gomi K . Stereotactic hypofractionated high-dose irradiation for stage I nonsmall cell lung carcinoma: clinical outcomes in 245 subjects in a Japanese multiinstitutional study. Cancer. 2004; 101(7):1623-31. DOI: 10.1002/cncr.20539. View

2.
Immerman S, Vanecko R, Fry W, HEAD L, SHIELDS T . Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg. 1981; 32(1):23-7. DOI: 10.1016/s0003-4975(10)61368-9. View

3.
Tada T, Minakuchi K, Koda M, Masuda N, Matsui K, Kawase I . Limited-stage small cell lung cancer: local failure after chemotherapy and radiation therapy. Radiology. 1998; 208(2):511-5. DOI: 10.1148/radiology.208.2.9680584. View

4.
Tada T, Minakuchi K, Matsui K, Kin H, Nishiguchi T, Fukuda H . A single institutional subset analysis of the WJLCG study comparing concurrent and sequential chemoradiotherapy for stage III non-small-cell lung cancer. Radiat Med. 2004; 22(3):163-7. View

5.
Kamel E, Zwahlen D, Wyss M, Stumpe K, von Schulthess G, Steinert H . Whole-body (18)F-FDG PET improves the management of patients with small cell lung cancer. J Nucl Med. 2003; 44(12):1911-7. View